Passa al contenuto
Merck

Vai a

M003

R-(−)-Deprenyl hydrochloride

≥98% (HPLC), MAO-B inhibitor, powder

Sinonimo/i:

(R)-(−)-N,α-Dimethyl-N-(2-propynyl)phenethylamine hydrochloride, R(−)-N-α-Dimethyl-N-2-propynyl-benzeneethanamine hydrochloride, Selegiline hydrochloride

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione
Taglio della confezioneSKUDisponibilitàPrezzo
250 mg
Per conoscere la disponibilità, visualizza il carrello
CHF 144.00
1 g
Per conoscere la disponibilità, visualizza il carrello
CHF 268.00

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C13H17N · HCl
Numero CAS:
Peso molecolare:
223.74
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:

CHF 144.00


Per conoscere la disponibilità, visualizza il carrello

Richiedi un ordine in blocco
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti


Nome del prodotto

R-(−)-Deprenyl hydrochloride, powder, ≥98% (HPLC)

Quality Level

assay

≥98% (HPLC)

form

powder

optical activity

[α]25/D −10.8°, c = 6.48 in H2O(lit.)

color

white

mp

141-142  °C

solubility

H2O: >10 mg/mL

originator

Sanofi Aventis

SMILES string

Cl[H].C[C@H](Cc1ccccc1)N(C)CC#C

InChI

1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1

InChI key

IYETZZCWLLUHIJ-UTONKHPSSA-N

Gene Information

human ... MAOB(4129)

Biochem/physiol Actions

Selective MAO-B inhibitor; anti-Parkinsonian agent.

Features and Benefits

This compound is featured on the Dopamine and Norepinephrine Metabolism and Histamine Synthesis and Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo
D3630D7071P8013
assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

98% (TLC)

form

powder

form

powder

form

powder

form

powder or crystals

Quality Level

100

Quality Level

200

Quality Level

100

Quality Level

200

solubility

H2O: >10 mg/mL

solubility

-

solubility

DMSO: ≥20 mg/mL

solubility

water: 50 mg/mL, clear, colorless to faintly yellow

color

white

color

-

color

white

color

-

originator

Sanofi Aventis

originator

Johnson & Johnson

originator

Eli Lilly

originator

-


pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral - STOT SE 3

target_organs

Central nervous system

Classe di stoccaggio

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti



Dominic Lomiwes et al.
Journal of agricultural and food chemistry, 72(30), 16777-16789 (2024-07-19)
Previous clinical studies indicate that monoamine oxidase-B (MAO-B) inhibition by blackcurrants must be predominantly attributed to bioactives other than anthocyanins. In this natural products discovery study, MAO-A/B inhibitory phytochemicals were isolated from blackcurrants, and a double-blind crossover study investigated the
Michael M Monaghan et al.
Neuro-degenerative diseases, 7(1-3), 153-159 (2010-03-04)
Parkinson's disease (PD) is a progressive neurodegenerative condition characterized by an increasing loss of dopaminergic neurons resulting in motor dysfunction. However, cognitive impairments in PD patients are a common clinical feature that has gained increased attention. The purpose of the
Olivia J Kalimon et al.
Experimental neurology, 363, 114356-114356 (2023-02-26)
Monoamine oxidase (MAO) is an enzyme located on the outer mitochondrial membrane that metabolizes amine substrates like serotonin, norepinephrine and dopamine. MAO inhibitors (MAOIs) are frequently utilized to treat disorders such as major depression or Parkinson's disease (PD), though their



Numero articolo commerciale globale

SKUGTIN
M003-250MG04061835557653
M003-1G04061835512720

Questions

Reviews

No rating value

Active Filters